anti mouse pd l1 antibody  (Bio X Cell)

Journal: JCI Insight

Article Title: DNA delivered by lipid nanoparticles induces CD8 + T cell–dependent antitumor responses and enhances anti–PD-L1 therapy

doi: 10.1172/jci.insight.197404

Figure Lengend Snippet: HDTVI-induced HCC models ( n = 11) were i.v. dosed with the indicated doses of DNA-LNP 4 weeks after HDTVI to observe a suboptimal antitumor effect. At days 1, 5, 8, and 11, 200 μg of anti–PD-L1 was i.p. dosed. ( A ) Tumor growth indicated by serum GLuc activity. ( B ) Survival curves of HCC-bearing mice. Survival data were analyzed by log-rank (Mantel-Cox) tests. * P < 0.05, ** P < 0.01, and ns (not significant).

Article Snippet: In some experiments, anti-mouse PD-L1 antibodies (InVivoMAb, BE0101 clone 10F.9G2, Bio X Cell) were administered via i.p. injection twice per week for a total of 2 weeks (4 doses) at a 200 μg/mouse dose in a total volume of 100 μL starting at day 1 after DNA-LNP dosing.

Techniques: Activity Assay

Journal: JCI Insight

Article Title: DNA delivered by lipid nanoparticles induces CD8 + T cell–dependent antitumor responses and enhances anti–PD-L1 therapy

doi: 10.1172/jci.insight.197404

Figure Lengend Snippet: B16-F10 tumor-bearing mice ( n = 8) were i.p. dosed with 250 μg of anti–PD-L1 and intratumorally dosed with indicated doses of DNA-LNP at days 0, 3, and 6. ( A ) Tumor growth curves. ( B ) Survival curves. Survival data were analyzed by log-rank (Mantel-Cox) tests. * P < 0.05, ** P < 0.01, *** P < 0.001, and ns (not significant).

Article Snippet: In some experiments, anti-mouse PD-L1 antibodies (InVivoMAb, BE0101 clone 10F.9G2, Bio X Cell) were administered via i.p. injection twice per week for a total of 2 weeks (4 doses) at a 200 μg/mouse dose in a total volume of 100 μL starting at day 1 after DNA-LNP dosing.

Techniques: